Iron Deficiency Injectable Market Report 2026

The iron deficiency injectable market size has grown strongly in recent years. It will grow from $15.22 billion in 2025 to $16.74 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia, limited efficacy of oral iron therapies, increasing chronic kidney disease cases, growth in hospital-based infusion treatments, wider clinical acceptance of injectable iron.

The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $25.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to rising geriatric population, increasing cancer and IBD prevalence, expansion of homecare infusion services, improved safety profiles of newer formulations, growing healthcare access in emerging markets. Major trends in the forecast period include rising preference for injectable iron over oral therapies, increasing use in chronic kidney disease management, growth of day-care and short-duration infusion protocols, expansion of generic injectable iron products, higher adoption in oncology and chronic disease treatment.

The rising prevalence of polycystic ovary syndrome (PCOS) is anticipated to drive the growth of the iron deficiency injectables market in the coming years. Polycystic ovary syndrome (PCOS) is a widespread hormonal disorder that affects individuals with ovaries, mainly women of reproductive age. PCOS can lead to iron deficiency due to excessive blood loss during menstruation, resulting in anemia, which can be treated with injectable iron deficiency medications. For example, in June 2023, the World Health Organization, a US-based specialized health agency, reported that globally, PCOS affects approximately 8-13% of women of reproductive age, with around 70% remaining undiagnosed. Consequently, the prevalence of polycystic ovary syndrome (PCOS) is contributing to the growth of the iron deficiency injectables market.

Major companies in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to maintain their market position. For example, in June 2023, Daiichi Sankyo Company, a US-based healthcare company, and American Regent Inc., a US-based injectables manufacturer, introduced INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which was approved by the Food and Drug Administration, a US-based government agency. This is the first and only intravenous iron replacement therapy for adult patients with chronic and progressive heart failure to receive FDA approval. Over 40 clinical trials involving more than 8,800 participants from various countries were conducted with INJECTAFER. This recent approval builds on INJECTAFER's proven and successful use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.

In November 2024, SteinCares, a health-focused company, collaborated with Pharmacosmos A/S to broaden its range of iron-deficiency therapies in the region. Through this collaboration, SteinCares and Pharmacosmos aim to enhance patient access to advanced intravenous iron treatments and improve the availability of evidence-based solutions for iron deficiency and iron-deficiency anemia. Pharmacosmos A/S is a Denmark-based pharmaceutical company specializing in iron therapy and hematology solutions.

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.

North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iron deficiency injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the iron deficiency injectable market by increasing costs for imported active pharmaceutical ingredients, excipients, and sterile manufacturing equipment, leading to pricing pressure and margin constraints for branded and generic manufacturers. Hospital and specialty clinic segments are most affected due to high-volume procurement, with asia-pacific and parts of europe experiencing greater disruption as key production and export hubs. However, tariffs are also encouraging local manufacturing, supply chain diversification, and investment in domestic pharmaceutical production, supporting long-term market resilience and regional self-sufficiency.

The iron deficiency injectable market research report is one of a series of new reports that provides iron deficiency injectable market statistics, including iron deficiency injectable industry global market size, regional shares, competitors with a iron deficiency injectable market share, detailed iron deficiency injectable market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency injectable industry. This iron deficiency injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Iron deficiency is a condition in which the body does not have enough iron, resulting in reduced production of red blood cells and hemoglobin. Iron deficiency injectables are medications or solutions administered via injection to treat iron deficiency. These injectable forms of iron enable direct delivery into the bloodstream, bypassing the digestive system.

The primary types of iron deficiency injectables include iron dextran, iron sucrose, and ferric carboxymaltose. Iron dextran is a combination of iron and a carbohydrate called dextran. The various forms, including branded and generic versions, are used in multiple applications such as chronic kidney disease, inflammatory bowel disease, cancer, and others, and are also utilized by different end users including hospitals, homecare services, specialty clinics, and more.

The iron deficiency injectable market consists of sales of ferumoxide, sodium ferric gluconate and iron gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.